AWM
LGND icon

Abound Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Abound Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317 Hold
1
– – ﹤0.01% 1018
2026
Q1 		$200 Hold
1
– – ﹤0.01% 1238
2025
Q4 		$190 Hold
1
– – ﹤0.01% 1201
2025
Q3 		$178 Hold
1
– – ﹤0.01% 1156
2025
Q2 		$114 Hold
1
– – ﹤0.01% 1223
2025
Q1 		$106 Sell
1
-1
-50% -$113 ﹤0.01% 1222
2024
Q4 		$215 Hold
2
– – ﹤0.01% 1032
2024
Q3 		$201 Buy
+2
New +$201 ﹤0.01% 1158

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
PWG
Portside Wealth Group Provo, Utah $858M AUM 26.82% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Abound Wealth Management's LGND Position: Q2 2026 in Review

Abound Wealth Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 1 share worth $317. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

Abound Wealth Management first reported a position in LGND in Q3 2024 and has held it in 8 quarters since. 36 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Abound Wealth Management held 1 share of Ligand Pharmaceuticals worth $317 as of Q2 2026.
  • Abound Wealth Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1018 holding.
  • Abound Wealth Management first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 36 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.